Skip to main content
KYTX
NASDAQ Life Sciences

Kyverna Initiates Rolling BLA Submission for miv-cel in Stiff Person Syndrome, Reports Strong Q1 Results

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.346
Mkt Cap
$619.225M
52W Low
$2.06
52W High
$13.67
52W Position info
402% above low
Off High info
24% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

KYTX has more than doubled off its 52-week low of $2.06.

Summary

Kyverna Therapeutics initiated its rolling BLA submission for miv-cel in Stiff Person Syndrome, a major regulatory milestone, alongside reporting strong Q1 financials and a cash runway into 2028.


Key Events · Product Development and Regulatory · KYTX

  • BLA Submission Initiated for miv-cel in SPS

    Kyverna began a rolling Biologics License Application (BLA) submission to the FDA for miv-cel in Stiff Person Syndrome (SPS), with FDA alignment on using a single-arm Phase 2 trial (KYSA-8) for support. The company expects to complete the submission in Q4 2026 and is seeking priority review under RMAT designation.

  • Strong Q1 Financial Results

    The company reported a net loss of $39.7 million for Q1 2026, an improvement from $44.6 million in Q1 2025. Cash, cash equivalents, and marketable securities stood at $236.4 million as of March 31, 2026, providing a cash runway into 2028.

  • Positive Clinical Data Updates

    Enrollment is advancing in the Phase 3 trial for generalized myasthenia gravis (gMG), supported by durable one-year efficacy data from the Phase 2 portion. Positive follow-up data for miv-cel in Progressive Multiple Sclerosis (PMS) were also presented.

  • Commercial Readiness

    Kyverna appointed Nadia Dac as Chief Commercial Officer and is advancing launch-readiness activities for miv-cel in SPS, with current manufacturing capacity expected to support commercial launch.


Analysis · KYTX · Life Sciences

Kyverna Therapeutics has initiated a rolling Biologics License Application (BLA) submission to the FDA for its lead CAR T-cell therapy, miv-cel, in Stiff Person Syndrome (SPS). This follows positive alignment with the FDA on using a single-arm Phase 2 trial (KYSA-8) to support the BLA, and the company is seeking priority review under its Regenerative Medicine Advanced Therapy (RMAT) designation. This marks a critical de-risking step towards commercialization for a first-in-class autoimmune CAR T therapy. The company also reported a reduced net loss and a strong cash position of $236.4 million, extending its cash runway into 2028, providing ample resources for continued development and launch preparations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KYTX was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $619.2M. The 52-week trading range was $2.06 to $13.67. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KYTX - Latest Insights

KYTX
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $4.18 info
Change: -$1.02 (-20%) info
Market Cap: $269.326M info
KYTX
Nov 12, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.20
Real-time Price: $4.18 info
Change: -$1.02 (-20%) info
Market Cap: $269.326M info
KYTX
Oct 23, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $4.18 info
Change: -$1.25 (-23%) info
Market Cap: $269.326M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $4.18 info
Change: -$2.87 (-41%) info
Market Cap: $269.326M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.19
Real-time Price: $4.18 info
Change: -$3.01 (-42%) info
Market Cap: $269.326M info